Meeting Report

2020–2021 Drug Updates: Investigational Therapeutics in the Pipeline

Donald C. Moore, PharmD, BCPS, BCOP, DPLA

From Levine Cancer Institute, Atrium Health, Charlotte, North Carolina

Presenter’s disclosure of conflicts of interest is found at the end of this article.


J Adv Pract Oncol 2022;13(3):286–291 | https://doi.org/10.6004/jadpro.2022.13.3.21 | © 2022 Harborside™


  

ABSTRACT

During JADPRO Live Virtual 2021, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mechanism of action, a rethinking of how to approach treating a disease, or those that have recently received FDA Breakthrough Designation status that advanced practitioners should be aware of.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.